Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Statement of Cash Flow (Unaudited)

v3.2.0.727
Condensed Consolidated Statement of Cash Flow (Unaudited) - USD ($)
6 Months Ended
Jun. 30, 2015
Jun. 30, 2014
Cash flows from operating activities    
Net loss for the period $ (3,408,028) $ (1,090,595)
Adjustments to reconcile net loss to net cash used in operating activities:    
Accrued interest and dividends on marketable securities 223 (15,695)
Depreciation and amortization 160,931 $ 173,647
Reserve for bad debts 864,000  
Gain from other non-operating activities $ (6,010) $ (4,669)
Non-cash share based compensation   549,600
Changes in assets and liabilities    
Increase in trade receivables $ (747,629) (926,766)
Increase in trade receivables - related party   $ (266,379)
Decrease in notes receivables - related party $ 131,566  
(Increase)/decrease in other receivables 7,578 $ (13,223)
Decrease in inventories 83,128 272,501
(Increase)/decrease in other assets (67,836) 62,246
Increase/(decrease) in trade and other payables $ 323,849 (362,198)
Decrease in other payables - related party   (6,586)
Decrease in deferred revenue - related party $ (305,556) (166,667)
Net cash used in operating activities (2,963,784) (1,794,784)
Cash flows from investing activities    
Purchases of property, plant and equipment (44,509) (1,660)
Purchases of marketable securities (34,555) $ (12,513,973)
Investment in Hainan Savy Akers Biosciences, Ltd. joint venture $ (64,091)  
Proceeds from demutualization of insurance carrier   $ 4,669
Proceeds from other non-operating activities $ 6,010  
Proceeds from sale of marketable securities 2,906,322 $ 1,081,329
Net cash provided by/(used in) investing activities $ 2,769,177 (11,429,635)
Cash flows from financing activities    
Payment of short-term note payable - related party   (307,500)
Proceeds from issuance of common shares   745,024
Net proceeds from issuance of common stock in initial public offering   13,101,336
Dividend distribution on Series A Convertible Preferred Stock   (15,793)
Net cash provided by financing activities   13,523,067
Net increase/(decrease) in cash $ (194,607) 298,648
Cash at beginning of period 455,841 103,634
Cash at end of period 261,234 402,282
Supplemental Schedule of Non-Cash Financing and Investing Activities    
Unrealized gains/(losses) on marketable securities 23,155 $ (3,549)
Issuance of restricted common share grants to directors and officers accrued in 2014 $ 697,300